XSTO
ALZCUR
Market cap90mUSD
Oct 09, Last price
6.76SEK
1D
0.30%
1Q
9.74%
IPO
-36.23%
Name
AlzeCure Pharma AB
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
20.65%
Rev. gr., 5y
%
Revenues
0
Net income
-48m
L+35.25%
CFO
-35m
L-1.51%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its products pipeline includes ACD856 for the treatment of Alzheimer’s disease, sleep disorders, depression, traumatic brain injuries, and Parkinson’s disease, which is in phase I clinical trial; ACD857, ACD679, and ACD680 that are in preclinical trial for the treatment of Alzheimer’s disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain indications; and ACD137, negative allosteric modulator (NAM) of TrkA receptors for osteoarthritic pain indications. The company was founded in 2012 and is based in Huddinge, Sweden.
Key people
Thomas Pollare
Chairman of the Board · since 2017
Johan Sandin
Chief Executive Officer · since 2017
Birgitta Lundvik
Chief Financial Officer · since 2018
Pontus Forsell
Director Pharmacology
Magnus Halldin
Director DMPK
Johan Lundkvist
Director Disease Biology
Gunnar Nordvall
Director Medicinal Chemistry
Matthias Rother
Medical Director
Ellen Donnelly
Independent Director · since 2018
Independent Director · since 2017
Pirkko Sulila Tamsen
Independent Director · since 2018
Headquarters & legal address
Hälsovägen 7
Huddinge, AB 141 57
SE
Huddinge, AB 141 57
SE
Address
Halsovagen 7
Huddinge, AB 141 57
SE
Huddinge, AB 141 57
SE
Previous name
Goldcup 14140 AB
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||